Furthermore, studies evaluating cost effectiveness of the various strategies have largely favoured universal testing, with initial IHC testing followed by BRAF mutation analysis for MLH1 absent tumours emerging as the most cost-effective approach [9]. The gene discussed is BRAF; the disease is neoplasm.